Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma.
Anobile DP, Bironzo P, Picca F, Lingua MF, Morena D, Righi L, Napoli F, Papotti MG, Pittaro A, Di Nicolantonio F, Gigliotti C, Bussolino F, Comunanza V, Guerrera F, Sandri A, Leo F, Libener R, Aviles P, Novello S, Taulli R, Scagliotti GV, Riganti C. Anobile DP, et al. Among authors: aviles p. Cancers (Basel). 2021 May 12;13(10):2332. doi: 10.3390/cancers13102332. Cancers (Basel). 2021. PMID: 34066159 Free PMC article.
Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.
Aviles P, Altares R, van Andel L, Lubomirov R, Fudio S, Rosing H, Márquez Del Pino FM, Tibben MM, Benedit G, Nan-Offeringa L, Luepke Estefan XE, Francesch A, Zeaiter A, Cuevas C, Schellens JHM, Beijnen JH. Aviles P, et al. Drug Metab Dispos. 2022 Apr;50(4):327-340. doi: 10.1124/dmd.121.000668. Epub 2022 Jan 18. Drug Metab Dispos. 2022. PMID: 35042701
Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
Céspedes MV, Guillén MJ, López-Casas PP, Sarno F, Gallardo A, Álamo P, Cuevas C, Hidalgo M, Galmarini CM, Allavena P, Avilés P, Mangues R. Céspedes MV, et al. Among authors: aviles p. Dis Model Mech. 2016 Dec 1;9(12):1461-1471. doi: 10.1242/dmm.026369. Epub 2016 Oct 20. Dis Model Mech. 2016. PMID: 27780828 Free PMC article.
Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.
Vidal A, Muñoz C, Guillén MJ, Moretó J, Puertas S, Martínez-Iniesta M, Figueras A, Padullés L, García-Rodriguez FJ, Berdiel-Acer M, Pujana MA, Salazar R, Gil-Martin M, Martí L, Ponce J, Molleví DG, Capella G, Condom E, Viñals F, Huertas D, Cuevas C, Esteller M, Avilés P, Villanueva A. Vidal A, et al. Among authors: aviles p. Clin Cancer Res. 2012 Oct 1;18(19):5399-411. doi: 10.1158/1078-0432.CCR-12-1513. Epub 2012 Aug 15. Clin Cancer Res. 2012. PMID: 22896654
MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding In Vivo Activity against HER2-Expressing Tumors.
Avilés P, Domínguez JM, Guillén MJ, Muñoz-Alonso MJ, Mateo C, Rodriguez-Acebes R, Molina-Guijarro JM, Francesch A, Martínez-Leal JF, Munt S, Galmarini CM, Cuevas C. Avilés P, et al. Mol Cancer Ther. 2018 Apr;17(4):786-794. doi: 10.1158/1535-7163.MCT-17-0795. Epub 2018 Feb 13. Mol Cancer Ther. 2018. PMID: 29440297
Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ. Harlow ML, et al. Cancer Res. 2016 Nov 15;76(22):6657-6668. doi: 10.1158/0008-5472.CAN-16-0568. Epub 2016 Oct 3. Cancer Res. 2016. PMID: 27697767 Free PMC article.
67 results